On the Human Right to Health: Statistical Lives, Contingent Persons, and Other Difficult Questions

Cambridge University Press, May 18, 2018
I. Glenn Cohen (Faculty Director)

From the article: In ethics and political philosophy, it is not uncommon to distinguish the question of who is a moral agent (one who bears moral responsibility) from the question of who is a moral patient (one to whom moral obligations are owed). The two need not…

Read More

Trump official on defensive as critics scoff at drug plan

The Hill , May 19, 2018
Peter Sullivan, quoting Rachel Sachs (Academic Fellow Alumna)

From the article: President Trump's health chief is struggling to show that the administration is serious about taking on drug companies after its proposals for lowering prices last week left big companies relieved and even spurred an uptick in their stock prices. …

Read More

Vermont Legislators Pass A Drug Importation Law. So What?

Kaiser Health News , May 18, 2018
Shefali Luthra, quoting Rachel Sachs (Academic Fellow Alumna)

From the article: This week, Vermont passed a first-in-the-nation law that would facilitate the state’s importation of prescription drugs wholesale from Canada. It represents the state’s effort to tackle head-on the issue of constantly climbing…

Read More

Trump spoke on lowering drug prices. The tweets rolled in

Stat, May 11, 2018
Andrew Joseph, quoting Rachel Sachs (Academic Fellow Alumna)

From the article: Given that President Trump is famous for his Earth-shaking tweets, it seems appropriate to comb through Twitter reactions to his administration’s new drug pricing plan, which was unveiled Friday. Many…

Read More

ICER Weekly View 05-18-18

Institute For Clinical and Economic Review, May 18, 2018
Mitchell Stein, citing Rachel Sachs (Academic Fellow Alumna)

From the article: Weekly View favorite (and Midwest CEPAC member) Rachel Sachs reviews the specific proposals in the speech in this Health Affairs blog.

Read More

FDA website to post names of drug makers blocking development of cheaper generics

Marketplace, May 17, 2018
Dan Gorenstein, quoting Rachel Sachs (Academic Fellow Alumna)

From the article: The FDA plans to unveil a website today naming pharmaceutical companies that have blocked the development of generic drugs by failing to provide samples to competitors. This public posting is part of FDA Commissioner Scott Gottlieb's larger crackdown…

Read More

Little Benefit to Breakthrough Cancer Drugs

Cancer Discovery, May 16, 2018
Catherine Caruso, quoting Jonathan J. Darrow (Student Fellow Alumnus)

From the article: In 2012, the FDA created the breakthrough therapy designation to speed up the development and review of drugs intended to treat serious or life-threatening diseases when preliminary clinical evidence indicates a possible substantial improvement over…

Read More

Trump’s Drug Pricing Speech Breaks Little New Ground, Largely Spares Industry

Health Affairs Blog, May 14, 2018
Rachel Sachs (Academic Fellow Alumna)

From the article: On Friday, President Donald Trump delivered a highly anticipated speech about drug pricing. The speech, coupled with the release of a “blueprint” providing more detail on the subject, was touted by administration officials as…

Read More

Trump promises to ‘derail the gravy train’ and lower drug prices in ‘American Patients First’ plan

The Washington Post , May 11, 2018
Carolyn Y. Johnson, quoting Rachel Sachs (Academic Fellow Alumna)

From the article:  President Trump promised to “derail the gravy train” in the health-care system Friday afternoon, in a Rose Garden speech in which he unveiled his much-anticipated strategy to lower drug prices. The…

Read More

The 6 most interesting parts of Trump’s mostly disappointing drug price plan

Vox, May 11, 2018
Dylan Scott, quoting Rachel Sachs (Academic Fellow Alumna)

From the article:  “We’re gonna see those prices go down. It’ll be a beautiful thing to watch,” President Donald Trump said in the Rose Garden on Friday. It’s a big promise. But the actual plan his administration put out doesn’t…

Read More

How to Make a Dent in Crazy-High Drug Prices

Bloomberg, May 11, 2018
By Austin Frakt, citing Rachel Sachs (Academic Fellow Alumna)

From the article: There’s no good reason to pay a lot for prescription drugs that don’t work well. But that’s what lots of Americans are doing. Some drug prices far outweigh any reasonable measure of the drug’s…

Read More

Do NFL Safety Concerns Mean Regulators Should Get in the Game?

Bloomberg Environment, April 26, 2018
Fatima Hussein, featuring report by the Law and Ethics Initiative of the Football Players Health Study at Harvard University

From the article: Concussions involving NFL players have been an increasing worry. Now a debate has resurfaced about whether federal safety regulators should be able to fine teams found guilty of inflicting serious blows to players’ heads.

Read More

Drug made famous by Shkreli’s 5,000% price hike is still $750 a pill

Ars Technica, May 4, 2018
Beth Mole, quoting W. Nicholson Price II (Academic Fellow Alumnus)

From the article: Disgraced ex-pharmaceutical executive and hedge fund manager Martin Shkreli is now behind bars, facing a seven-year prison sentence for securities fraud. Yet the drug-price hike that initially thrust him into the public spotlight—and infamy—hasn’t…

Read More

For Shame: ‘Pharma Bro’ Shkreli Is In Prison, But Daraprim’s Price Is Still High

Washington Post, May 4, 2018
Shefali Luthra, quoting W. Nicholson Price II (Academic Fellow Alumnus)

From the article: The continued high price of the drug is a cautionary tale to those who hope that public shaming of a few “bad actors” can curb escalating drug prices, because the problem is rooted in the market’s underlying financial incentives. …

Read More

Trump is set to unveil his plan to lower drug prices. Here are four things to watch for.

The Washington Post, May 10, 2018
Carolyn Y. Johnson, quoting Rachel Sachs (Academic Fellow Alumna)

From the article: President Trump will deliver Friday afternoon a twice-delayed, much-anticipated speech about his plan to lower drug prices — after a year when harsh rhetoric against drugmakers was accompanied by little action.

Read More

Work Requirements Give Republicans Cover to Expand Medicaid

U.S. News, April 23, 2018
Gabrielle Levy, quoting Allison K. Hoffman (Academic Fellow Alumna)

From the article: While the Medicaid law sets certain mandatory minimums of eligibility and coverage, the waiver program allows states wide latitude to run their programs as they see fit. For state Republican lawmakers demonstrating a willingness to consider Medicaid…

Read More

HealthAffairs Podcast: Precision Medicine

Health Affairs Podcast, May 8, 2018
Jonathan J. Darrow (Student Fellow Alumnus), Alan Weil, Geoffrey Ginsburg, Alessandro Blasimme, Kathryn A. Phillips, Daryl Pritchard,

Overview of the Podcast: The May 2018 issue of Health Affairs on "Precision Medicine," contains a timely and comprehensive look at the use of data and genetic information to better diagnose and treat patients. It features real world examples of how precision medicine…

Read More

Authorities Use DNA Testing Service to Identify “Golden State Killer” - What Does This Mean for You?

WCIA, The Takeaway, May 7, 2018
Heather Goldstone & Elsa Partan, quoting I. Glenn Cohen (Faculty Director)

From the article: Late last month, authorities charged a man in Sacramento County, California as the so-called Golden State Killer after tracking him down with a private DNA test company, one called GEDmatch.  Joseph James DeAngelo is accused of…

Read More

Planned Parenthood sues Trump administration over federal funding

The Washington Times, May 2, 2018
Alex Swoyer, quoting I. Glenn Cohen (Faculty Director)

From the article: Three Planned Parenthood affiliates sued Wednesday to demand taxpayer money keep flowing to the country’s largest abortion network, saying a new Trump administration policy appears designed to cut them out of family planning money. …

Read More

For Shame: ‘Pharma Bro’ Shkreli Is In Prison, But Daraprim’s Price Is Still High

The Washington Post , May 4, 2018
Shefali Luthra, quoting W. Nicholson Price (Academic Fellow Alumnus)

From the article: It was 2015 when Martin Shkreli, then CEO of Turing Pharmaceuticals and the notorious “pharma bro,” jacked up the cost of the lifesaving drug Daraprim by 5,000 percent. Overnight, its price tag skyrocketed from $13.50…

Read More